Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | STAT6 | P42226 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1'-Acetoxychavicol Acetate SCHEMBL17454871 | 1.00 | LMNA (0.47) | LMNAHSD17B10MAPTKDM4ECYP3A4 | |
| SCHEMBL22130943 | 0.90 | LMNA (0.44) | LMNAHSD17B10MAPTKDM4ECYP3A4 | |
| SCHEMBL29034768 | 0.87 | MAPT (0.44) | LMNAMAPTKDM4ECYP3A4PKM | |
| SCHEMBL29034776 | 0.81 | TPMT (0.35) | MAPTKDM4ECYP3A4SLC6A3TSHR | |
| SCHEMBL61038 | 0.81 | CYP3A4 (0.50) | LMNAHSD17B10MAPTKDM4ECYP3A4 | |
| SCHEMBL5696969 | 0.81 | ELANE (0.51) | LMNAKDM4ECYP3A4ESR1SLC6A3 | |
| SCHEMBL4174338 | 0.80 | TSHR (0.45) | LMNAKDM4ECYP3A4HIF1ATSHR | |
| SCHEMBL9642843 | 0.79 | PTGS2 (0.46) | MAPTCYP3A4PKMCYP2C9PDE4A | |
| SCHEMBL5638474 | 0.78 | ALDH1A1 (0.45) | MAPTKDM4ECYP3A4CYP2C9TSHR | |
| SCHEMBL4174537 | 0.77 | KDM4E (0.48) | LMNAHSD17B10MAPTKDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4425628-B2 | — | — | 2010-03-03 | — | — | JP | claimed |
| EP-1435894-A4 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO PHARMACEUTICALS INC (US) | 2005-07-06 | — | — | EP | claimed |
| JP-2005505519-A | — | — | 2005-02-24 | — | — | JP | claimed |
| EP-1435894-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | Galileo Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | claimed |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-04-17 | — | — | US | claimed |
| WO-2003009807-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO LABORATORIES, INC. (US) | 2003-02-06 | — | — | WO | claimed |
| EP-4066897-A1 | COMPOSITION FOR PREVENTING DECREASE IN MUSCLE MASS, PREVENTING WEAKNESS OF MUSCULAR POWER, INCREASING MUSCLE MASS OR STRENGTHENING MUSCULAR POWER | Suntory Holdings Limited (JP) | 2022-10-05 | — | — | EP | disclosed |
| US-20150231045-A1 | ANTI-DANDRUFF COMPOSITION COMPRISING 1-ACETOXYCHAVICOL ACETATE | ANALYTICON DISCOVERY GMBH (DE) | 2015-08-20 | — | — | US | disclosed |
| US-20150231045-A1 | ANTI-DANDRUFF COMPOSITION COMPRISING 1-ACETOXYCHAVICOL ACETATE | ANALYTICON DISCOVERY GMBH (DE) | 2015-08-20 | — | — | US | disclosed |
| WO-2014037529-A9 | ANTI-DANDRUFF COMPOSITION | ANALYTICON DISCOVERY GMBH (DE) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014037529-A2 | ANTI-DANDRUFF COMPOSITION | ANALYTICON DISCOVERY GMBH (DE) | 2014-03-13 | — | — | WO | disclosed |
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20060178356-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| EP-1435894-A4 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO PHARMACEUTICALS INC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050142155-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| EP-1435894-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | Galileo Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003009807-A2 | CYTOPROTECTIVE COMPOUNDS, PHARMACEUTICAL AND COSMETIC FORMULATIONS, AND METHODS | GALILEO LABORATORIES, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050142155-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | LMNA 900/4885HSD17B10 638/4885MAPT 2548/4885 |
| US-20030073712-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | LMNA 900/4885HSD17B10 638/4885MAPT 2548/4885 |
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | TRPV1, TRPC4, TRPC3 | LMNA 2687/4885HSD17B10 3304/4885MAPT 3407/4885 |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | LMNA 900/4885HSD17B10 638/4885MAPT 2548/4885 |
| US-20060178356-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | LMNA 900/4885HSD17B10 638/4885MAPT 2548/4885 |
| US-20150231045-A1 | ANTI-DANDRUFF COMPOSITION COMPRISING 1-ACETOXYCHAVICOL ACETATE | GANAB, GANC, AMY1A | LMNA 1465/4885HSD17B10 47/4885MAPT 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.